Eplerenone use in preventing AF recurrence post-ablation
TSUKUBA, JAPAN. In my March 2003 research report Aldosterone: Villain of the Peace?, I speculated that excess aldosterone or cortisol was implicated in the initiation of paroxysmal atrial fibrillation (AF) episodes and was also responsible for fibrosis of the heart tissue, eventually leading to persistent or permanent AF. I also suggested that blocking mineralocorticoid (MC) receptors with aldosterone antagonists (spironolactone or eplerenone) may be effective in preventing AF episodes. Now Japanese cardiologists report that the aldosterone antagonist eplerenone (Inspra) is effective in preventing recurrence of AF in patients with permanent (long-standing persistent) AF who have undergone radiofrequency (RF) catheter ablation.
Their clinical trial included 161 patients who had been in sustained AF for anywhere from 1 to 20 years (mean of 3.4 years). The average age was 60 years and 83% were male. Only 12% of the group had structural heart disease, so the majority had lone AF. All participants underwent an extensive RF catheter ablation using the double-Lasso technique and an open-irrigation catheter. A right atrial flutter ablation was also included. Following the procedure, 55 patients were assigned to receive eplerenone (dosage not specified, but likely 25-50 mg/day). In addition, beta-blockers, ACE inhibitors, ARBs (angiotensin receptor blockers), and calcium channel blockers were used equally in the group of 55 patients receiving eplerenone and in the group of 106 patients not receiving eplerenone.
At the end of 24 months of follow-up, 47% of participants were still in normal sinus rhythm (NSR). Those who had been in permanent AF for more than 3 years were significantly less likely to be in NSR as were patients with an enlarged left atrium. Experiencing AF during the first 3 months following the ablation (early recurrence) was also associated with a significantly poorer outcome. Substantially more patients in the eplerenone group (60%) were in NSR after 24 months than in the non-eplerenone group (40%).
The Japanese researchers conclude that eplerenone therapy substantially increases the odds of maintaining NSR after a catheter ablation for permanent AF.
Ito, Y, et al. Effect of eplerenone on maintenance of sinus rhythm after catheter ablation in patients with long-standing persistent atrial fibrillation. American Journal of Cardiology, January 19, 2013 [Epub ahead of print]
Their clinical trial included 161 patients who had been in sustained AF for anywhere from 1 to 20 years (mean of 3.4 years). The average age was 60 years and 83% were male. Only 12% of the group had structural heart disease, so the majority had lone AF. All participants underwent an extensive RF catheter ablation using the double-Lasso technique and an open-irrigation catheter. A right atrial flutter ablation was also included. Following the procedure, 55 patients were assigned to receive eplerenone (dosage not specified, but likely 25-50 mg/day). In addition, beta-blockers, ACE inhibitors, ARBs (angiotensin receptor blockers), and calcium channel blockers were used equally in the group of 55 patients receiving eplerenone and in the group of 106 patients not receiving eplerenone.
At the end of 24 months of follow-up, 47% of participants were still in normal sinus rhythm (NSR). Those who had been in permanent AF for more than 3 years were significantly less likely to be in NSR as were patients with an enlarged left atrium. Experiencing AF during the first 3 months following the ablation (early recurrence) was also associated with a significantly poorer outcome. Substantially more patients in the eplerenone group (60%) were in NSR after 24 months than in the non-eplerenone group (40%).
The Japanese researchers conclude that eplerenone therapy substantially increases the odds of maintaining NSR after a catheter ablation for permanent AF.
Ito, Y, et al. Effect of eplerenone on maintenance of sinus rhythm after catheter ablation in patients with long-standing persistent atrial fibrillation. American Journal of Cardiology, January 19, 2013 [Epub ahead of print]
The AFIB Report, Forum and Database do not provide medical advice. Do not attempt self-diagnosis or self-treatment based on our reports.
Donate Today!
Please donate to The AFIB Report, using one of the two buttons below.
A third donation method, beyond choosing either the Donate with PayPal or Donate with Credit/Debit card described elsewhere on this site, is for those who prefer to directly mail a check or money order to our business address at: The AFIB Report, A Non-Profit 501(c)(3) Corporation, C/O Shannon Dickson, P.O. Box 1016, Sedona, Arizona 86339. Any of the three donation options are fine with us based on each donor's preference, and with our sincere gratitude!
A third donation method, beyond choosing either the Donate with PayPal or Donate with Credit/Debit card described elsewhere on this site, is for those who prefer to directly mail a check or money order to our business address at: The AFIB Report, A Non-Profit 501(c)(3) Corporation, C/O Shannon Dickson, P.O. Box 1016, Sedona, Arizona 86339. Any of the three donation options are fine with us based on each donor's preference, and with our sincere gratitude!
The AFIB Report, A Non-Profit Tax-Exempt 501(c)(3) Corporation
Learn